GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biora Therapeutics Inc (STU:4ZU0) » Definitions » EV-to-EBITDA

Biora Therapeutics (STU:4ZU0) EV-to-EBITDA : -0.56 (As of May. 30, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Biora Therapeutics EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Biora Therapeutics's enterprise value is €52.67 Mil. Biora Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was €-93.87 Mil. Therefore, Biora Therapeutics's EV-to-EBITDA for today is -0.56.

The historical rank and industry rank for Biora Therapeutics's EV-to-EBITDA or its related term are showing as below:

STU:4ZU0' s EV-to-EBITDA Range Over the Past 10 Years
Min: -4.5   Med: -1.7   Max: -0.15
Current: -0.57

During the past 6 years, the highest EV-to-EBITDA of Biora Therapeutics was -0.15. The lowest was -4.50. And the median was -1.70.

STU:4ZU0's EV-to-EBITDA is ranked worse than
100% of 451 companies
in the Biotechnology industry
Industry Median: 9.3 vs STU:4ZU0: -0.57

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-30), Biora Therapeutics's stock price is €0.535. Biora Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was €-6.637. Therefore, Biora Therapeutics's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Biora Therapeutics EV-to-EBITDA Historical Data

The historical data trend for Biora Therapeutics's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biora Therapeutics EV-to-EBITDA Chart

Biora Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial - -3.43 -2.54 -3.43 -0.61

Biora Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.27 -3.01 -1.09 -0.61 -0.69

Competitive Comparison of Biora Therapeutics's EV-to-EBITDA

For the Biotechnology subindustry, Biora Therapeutics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biora Therapeutics's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biora Therapeutics's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Biora Therapeutics's EV-to-EBITDA falls into.



Biora Therapeutics EV-to-EBITDA Calculation

Biora Therapeutics's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=52.674/-93.868
=-0.56

Biora Therapeutics's current Enterprise Value is €52.67 Mil.
Biora Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-93.87 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biora Therapeutics  (STU:4ZU0) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Biora Therapeutics's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.535/-6.637
=At Loss

Biora Therapeutics's share price for today is €0.535.
Biora Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-6.637.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Biora Therapeutics EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Biora Therapeutics's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Biora Therapeutics (STU:4ZU0) Business Description

Traded in Other Exchanges
Address
4330 La Jolla Village Drive, Suite 300, San Diego, CA, USA, 92122
Biora Therapeutics Inc is a biotechnology company engaged in developing oral biotherapeutics. Its drug-device combinations could enable new treatment approaches in the delivery of therapeutics in two main areas: Targeted delivery of therapeutics to the site of disease in the gastrointestinal ("GI") tract, which is designed to improve outcomes for patients with Inflammatory Bowel Disease (IBD); and Systemic delivery of biotherapeutics, which are designed to replace injection with needle-free, oral delivery technology. Geographically, it operates only in the United States.

Biora Therapeutics (STU:4ZU0) Headlines

No Headlines